Endpoints shares our FDA letter

Adding to the list of larger news outlets covering what APC is up to is Endpoints News (from the Financial Times). It wrote about our letter to the FDA that pointed out that semaglutide isn’t difficult to compound, despite erroneous claims by Novo Nordisk.